IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
Top Cited Papers
- 31 July 2012
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 130 (1), 145-154.e9
- https://doi.org/10.1016/j.jaci.2012.04.024
Abstract
No abstract availableFunding Information
- Eli Lilly and Company
This publication has 55 references indexed in Scilit:
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque PsoriasisThe New England Journal of Medicine, 2012
- The IL-23/Th17 Axis in the Immunopathogenesis of PsoriasisJournal of Investigative Dermatology, 2009
- Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic CellsJournal of Investigative Dermatology, 2009
- Cytokines that regulate autoimmunityCurrent Opinion in Immunology, 2008
- Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to PsoriasisThe Journal of Immunology, 2008
- Induction of IL-17+ T Cell Trafficking and Development by IFN-γ: Mechanism and Pathological Relevance in PsoriasisThe Journal of Immunology, 2008
- Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathwaysBritish Journal of Dermatology, 2008
- Type I Interferon: Potential Therapeutic Target for Psoriasis?PLOS ONE, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Th17 Cells and Autoimmune Encephalomyelitis (EAE/MS)Allergology International, 2008